Markets
markets

Wall Street thinks Palantir shares are wildly overvalued

Shares of defense- and intelligence-software company Palantir are up for the third straight session Thursday, making up some of the ground they lost during their 20% tumble to start this year on the heels of an outstanding 2024.

Palantir’s roughly 340% gain last year, supercharged by wild enthusiasm from a rabid base of retail shareholders, made it the biggest gainer in the S&P 500.

Wall Street’s professional Palantir watchers, however, are much more skeptical. The consensus target price for Palantir shares is $46.38, about 35% below where the stock is currently trading (~$70.25).

It’s not like analysts think Palantir’s business is in trouble. In fact, they’ve been more or less steadily ramping up estimates for sales and profit throughout the year, citing better-than-expected performance of Palantir’s AI offerings with commercial clients as well as the ongoing growth of its business with the US government.

Analysts now anticipate that when Palantir reports on Feb. 3, the firm will show some $778 million in revenues for the fourth quarter, up 28% from the prior year.

But the bottom line isn’t as thrilling. Net income, on a GAAP basis, is expected to rise roughly 11% to $103.5 million.

Whether such numbers matter at all for the trajectory of the stock over the short term is a completely different question. The enthusiasm surrounding Palantir over the last year was always more of a vibes-based, retail-trading phenomenon than the rational outcome of rigorous analytic efforts.

But as the steep drop that Palantir suffered early this year shows, when the momentum around highly valued stocks stalls, things can get hairy fast.

More Markets

See all Markets
markets

Spectrum owner Charter Communications is on pace for its worst day ever as broadband numbers and Q1 results disappoint

Cable and broadband company Charter Communications is on pace for its worst-ever trading day on Friday, as investors dump the stock following its Q1 results and forward guidance.

Charter, which owns Spectrum, reported adjusted earnings of $9.17 per share, below Wall Street estimates of $9.96 per share from analysts polled by FactSet. On the company’s earnings call, CFO Jessica Fischer appeared to lower its guidance for full-year revenue per user.

“It’ll be close either way in terms of whether we end up with net growth,” Fischer said.

The company lost 120,000 internet subscribers in the quarter, deeper than the expected 94,800 and double its loss from the same period last year. That news comes one day after Comcast’s earnings provided a bit of optimism for broadband as a category: the company reported Q1 losses of 65,000, significantly improving from 183,000 losses in the same quarter last year. Comcast is down more than 10%, on pace for its worst day since January 2025.

markets
Luke Kawa

Nvidia poised to snap longest run without a record close since the AI boom began

The stock price of the company responsible for the brains of the AI boom is finally showing some brawn again.

Nvidia, the world’s most valuable company, is poised to close at a record high for the first time since October 29, 2025, on Friday (if it ends above $207.04).

The AI chip trade is on fire, with the Philadelphia Semiconductor Index slated to deliver its 18th consecutive gain as Intel’s robust results and outlook juice the entire ecosystem. Hyperscalers report earnings next week, and their capex guidance can be thought of as the earnings guidance for Nvidia and other AI suppliers for the quarters to come.

This would end Nvidia’s longest stretch without a record close since the unofficial start of the AI boom (when the chip designer delivered blowout quarterly results in May 2023).

(Sorry if I jinx this!)

markets

Lilly slips after prescriptions for its weight-loss pill come in below expectations in second week

Eli Lilly fell on Friday after prescription data for its new weight-loss pill, Foundayo, showed that it’s having a significantly slower rollout than its top competitor.

The pill was prescribed about 3,700 times in its second week, according to IQVIA data cited by Deutsche Bank analysts, compared to the roughly 8,000 they were expecting. Novo Nordisk’s Wegovy pill, which came out in January, hit over 18,000 prescriptions in its second week.

The FDA approved Foundayo on April 1 and shipments began on April 9. Deutsche analysts noted that Lilly’s GLP-1 injections, which currently outsell Novo’s, also had a slower start.

Lilly fell more than 4% after the numbers were released. Novo Nordisk rose more than 5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.